By Ben Glickman
Shares of Bluebird bio fell after the company’s sickle-cell disease treatment received a black-box warning and was announced at a higher price point than a competitor’s treatment.
The stock was down 41% to $2.84 on Friday. Shares are down 60% this year.
The company’s Lyfgenia was approved by the Food and Drug Administration for the treatment of sickle-cell disease. The FDA also approved Casgevy, a sickle-cell treatment developed by Vertex Pharmaceuticals and CRISPR Therapeutics using Crispr gene-modification technology.
The FDA said that Lyfgenia would include a black-box warning related to certain cases of blood cancer in patients treated with the drug.
Bluebird said the treatment would come with a $3.1 million price tag, compared with the $2.2 million price for Casgevy.
Evercore analysts said in a research note that the announcements gave Casgevy an advantage because of its lack of black-box label and lower price.
Write to Ben Glickman at ben.glickman@wsj.com
Read the full article here